Cross-talk between HER2 and MED1 regulates tamoxifen resistance of human breast cancer cells

Cancer Research

Volumn 72, Issue 21, 2012, Pages 5625-5634

  Cui, Jiajun ^a   Germer, Katherine ^a   Wu, Tianying ^b   Wang, Jiang ^a   Luo, Jia ^d   Wang, Shao Chun ^a   Wang, Qianben ^c   Zhang, Xiaoting ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b Division of Epidemiology and Biostatistics   (United States)

^c THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; NUCLEAR RECEPTOR COREPRESSOR; SILENCING MEDIATOR OF RETINOID AND THYROID HORMONE RECEPTOR; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER RESISTANCE; CONTROLLED STUDY; ENZYME ACTIVATION; GENE; GENE OVEREXPRESSION; GENE TARGETING; HER2 GENE; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REPRESSOR GENE; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TISSUE MICROARRAY;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MCF-7 CELLS; MEDIATOR COMPLEX SUBUNIT 1; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR CROSS-TALK; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TAMOXIFEN; TISSUE ARRAY ANALYSIS; TRANSFECTION;

EID: 84868228009     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-1305     Document Type: Article

References (49)

1. Couse JF, Korach KS. Estrogen receptor null mice: what have we learned and where will they lead us? Endocr Rev 1999;20:358-417.
2. Russo J, Hu YF, Yang X, Russo IH. Developmental, cellular, and molecular basis of human breast cancer. J Natl Cancer Inst Monogr 2000;(27):17-37.
3. Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med 2001;344:276-85.
4. Gruber CJ, Tschugguel W, Schneeberger C, Huber JC. Production and actions of estrogens. N Engl J Med 2002;346:340-52.
5. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006;354:270-82.
6. Clarke R, Skaar TC, Bouker KB, Davis N, Lee YR, Welch JN, et al. Molecular and pharmacological aspects of antiestrogen resistance. J Steroid Biochem Mol Biol 2001;76:71-84.
7. Ali S, Coombes RC. Endocrine-responsive breast cancer and strate-gies for combating resistance. Nat Rev Cancer 2002;2:101-12.
8. Riggs BL, Hartmann LC. Selective estrogen-receptor modulators -mechanismsof action and application toclinical practice. N Engl J Med 2003;348:618-29.
9. Herynk MH, Fuqua SA. Estrogen receptors in resistance to hormone therapy. Adv Exp Med Biol 2007;608:130M43.
10. Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 2011;62:233-47.
11. Osborne CK, Shou J, Massarweh S, Schiff R. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 2005;11:865s-70s.
12. Gee JM, Howell A, Gullick WJ, Benz CC, Sutherland RL, Santen RJ, et al. Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and impli-cations for future treatment. Endocr Relat Cancer 2005;12 Suppl 1: S1-7.
13. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007;357:39-51.
14. Kurokawa H, Lenferink AE, Simpson JF, Pisacane PI, Sliwkowski MX, Forbes JT, et al. Inhibition of HER2/neu (erb B-2) and mitogen-activat-ed protein kinases enhances tamoxifen action against HER2-over-expressing, tamoxifen-resistant breast cancer cells. Cancer Res 2000;60:5887-94.
15. Yarden Y, Sliwkowski MX.Untanglingthe Erb Bsignalling network. Nat Rev Mol Cell Biol 2001;2:127-37.
16. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Can-cer Inst 2004;96:926-35.
17. Arpino G, Green SJ, Allred DC, Lew D, Martino S, Osborne CK, et al. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res 2004;10:5670-6.
18. Witters LM, Kumar R, Chinchilli VM, Lipton A. Enhanced anti-prolifer-ative activity of the combination of tamoxifen plus HER-2-neu anti-body. Breast Cancer Res Treat 1997;42:1-5.
19. Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 1992;24:85-95.
20. Takimoto GS, Graham JD, Jackson TA, Tung L, Powell RL, Horwitz LD, et al. Tamoxifen resistant breast cancer: coregulators determine the direction of transcription by antagonist-occupied steroid receptors. J Steroid Biochem Mol Biol 1999;69:45-50.
21. Font de Mora J, Brown M. AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol Cell Biol 2000;20:5041-7.
22. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, et al.Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 2003;95:353-61.
23. Roeder RG.Theroleofgeneralinitiationfactorsintranscriptionby RNA polymerase II. Trends Biochem Sci 1996;21:327-35.
24. Roeder RG. Role of general and gene-specific cofactors in the regu-lation of eukaryotic transcription. Cold Spring Harb Symp Quant Biol 1998;63:201-18.
25. Zhu Y, Qi C, Jain S, Le Beau MM, Espinosa R III, Atkins GB, et al. Amplification and overexpression of peroxisome proliferator-activated receptor binding protein (PBP/PPARBP) gene in breast cancer. Proc Natl Acad Sci U S A 1999;96:10848-53.
26. Burakov D, Wong CW, Rachez C, Cheskis BJ, Freedman LP. Func-tional interactions between the estrogen receptor and DRIP205, a subunit of the heteromeric DRIP coactivator complex. J Biol Chem 2000;275:20928-34.
27. Warnmark A, Almlof T, Leers J, Gustafsson JA, Treuter E. Differential recruitment of the mammalian mediator subunit TRAP220 by estrogen receptors ERalpha and ERbeta. J Biol Chem 2001;276:23397-404.
28. Kang YK, Guermah M, Yuan CX, Roeder RG. The TRAP/Mediator coactivator complex interacts directly with estrogen receptors alphaand betathroughthe TRAP220subunitand directlyenhances estrogen receptor function in vitro. Proc Natl Acad Sci U S A 2002;99:2642-7.
29. Zhang X, Krutchinsky A, Fukuda A, Chen W, Yamamura S, Chait BT, et al. MED1/TRAP220 exists predominantly in a TRAP/Mediator sub-population enriched in RNA polymerase II and is required for ER-mediated transcription. Mol Cell 2005;19:89-100.
30. Jiang P, Hu Q, Ito M, Meyer S, Waltz S, Khan S, et al. Keyrolesfor MED1 Lxx LL motifs in pubertal mammary gland development and luminal-cell differentiation. Proc Natl Acad Sci U S A 2010;107:6765-70.
31. Misra P, Owuor ED, Li W, Yu S, Qi C, Meyer K, et al. Phosphorylation of transcriptional coactivator peroxisome proliferator-activated receptor (PPAR)-binding protein (PBP). Stimulation of transcriptional regulation by mitogen-activated protein kinase. J Biol Chem 2002;277:48745-54.
32. Pandey PK, Udayakumar TS, Lin X, Sharma D, Shapiro PS, Fondell JD. Activation of TRAP/mediatorsubunit TRAP220/Med1 is regulated by mitogen-activated protein kinase-dependent phosphorylation. Mol Cell Biol 2005;25:10695-710.
33. Belakavadi M, Pandey PK, Vijayvargia R, Fondell JD. MED1 phos-phorylation promotes its association with mediator: implications for nuclear receptorsignaling. Mol Cell Biol 2008;28:3932-42.
34. Chen Z, Zhang C, Wu D, Chen H, Rorick A, Zhang X, et al. Phospho-MED1-enhanced UBE2C locus looping drives castration-resistant prostate cancer growth. EMBO J 2011;30:2405-19.
35. Luoh SW. Amplification and expression of genes from the 17q11 approximately q12 amplicon in breast cancer cells. Cancer Genet Cytogenet 2002;136:43-7.
36. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A 2005;102:13550-5.
37. Ivshina AV, George J, Senko O, Mow B, Putti TC, Smeds J, et al. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 2006;66:10292-301.
38. Wang SC, Lien HC, Xia W, Chen IF, Lo HW, Wang Z, et al. Binding at and transactivation of the COX-2 promoter by nucleartyrosine kinase receptor Erb B-2. Cancer Cell 2004;6:251-61.
39. Zhang D, Jiang P, Xu Q, Zhang X. ARGLU1 interacts with MED1 and is required forestrogen receptor-mediated genetranscription and breast cancer cell growth. J Biol Chem 2011;286:17746-54.
40. Lupien M, Meyer CA, Bailey ST, Eeckhoute J, Cook J, Westerling T, et al. Growth factor stimulation induces a distinct ER(alpha) cistrome underlying breast cancer endocrine resistance. Genes Dev 2011;24: 2219-27.
41. Shang Y, Hu X, Di Renzo J, Lazar MA, Brown M.Cofactordynamicsand sufficiency in estrogen receptor-regulated transcription. Cell 2000;103:843-52.
42. Hurtado A, Holmes KA, Geistlinger TR, Hutcheson IR, Nicholson RI, Brown M, et al. Regulation of ERBB2 by oestrogen receptor-PAX2 determines responsetotamoxifen. Nature 2008;456:663-6.
43. Smith CL, Nawaz Z, O'Malley BW. Coactivator and corepressor regulationoftheagonist/antagonistactivityofthemixedantiestrogen, 4-hydroxytamoxifen. Mol Endocrinol 1997;11:657-66.
44. Keeton EK, Brown M. Cell cycle progression stimulated by tamoxifen-bound estrogen receptor-alpha and promoter-specific effects in breast cancer cells deficient in N-Co R and SMRT. Mol Endocrinol 2005;19:1543-54.
45. Shang Y, Brown M. Moleculardeterminantsforthetissuespecificityof SERMs. Science 2002;295:2465-8.
46. Bunone G, Briand PA, Miksicek RJ, Picard D. Activation of the unli-ganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J 1996;15:2174-83.
47. Lee AV, Cui X, Oesterreich S. Cross-talk among estrogen receptor, epidermalgrowthfactor, andinsulin-likegrowthfactorsignalinginbreast cancer. Clin Cancer Res 2001;7:4429s-35s; discussion 11s-12s.
48. Creighton CJ, Casa A, Lazard Z, Huang S, Tsimelzon A, Hilsenbeck SG, et al. Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol 2008;26:4078-85.
49. Ross-Innes CS, Stark R, Teschendorff AE, Holmes KA, Ali HR, Dunning MJ, et al. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 2012;481:389-93.